Kirby is rated HOLD at $140.82 with a base target of $155.23, reflecting moderate near-term upside. The company's marine segment is the main profit driver, showing a 17% revenue increase and 26% operating profit growth in Q3. Distribution & Services also demonstrate real growth, while the data center business is not yet central to the investment thesis. Despite operational recovery, concerns remain about cash flow conversion and margin sustainability, leading to a recommendation to consider buying only below $125 or after stronger cash flow evidence, as current valuation already factors in much of the improvement.
Kirby stock's recent performance is presented here alongside Industrials-sector data from Pluang as of Nov 06, 2026 10:31 WIB. Among 135 priced US Industrials stocks on Pluang, only 11 rose while 124 fell. Notable movers include FLUX down 29.99% at USD 0.29 with a typical hold time of 24 days and a buy order activity of 57%, RDW down 17.49% at USD 6.37 with 91% buy orders, and FPS down 16.67% at USD 18.70 with all orders buying and a very short hold time of 5 days.
The 2026 Global Health Congress in New York gathered over 625 healthcare leaders from 25 countries to discuss innovation, equity, and investment in healthcare. The event featured 350+ startup applications in its Healthcare Shark Tank competition, cro...
Ambarella, an edge AI semiconductor company, announced its third quarter fiscal year 2027 earnings conference call will be held on November 24, 2026, at 1:30 p.m. Pacific Time. The company will release its earnings report after the market closes that...
U.S. spot ETFs tracking Hyperliquid (HYPE) experienced $2.3787 million in net outflows on November 4, reversing the previous day's $605,100 inflow. Bitwise Hyperliquid ETF led the outflows with $1.411 million withdrawn, while 21Shares Hyperliquid ETF...
A trader's Bitcoin position worth $15.6 million was liquidated during recent market declines, forcing the closure of the position due to insufficient collateral. Following this, the trader opened a new short position valued at $2.68 million on TRUMP ...
INOVIO Pharmaceuticals announced a public offering of approximately 58.7 million shares and pre-funded warrants to raise about $75 million before expenses. The offering price is set at $1.05 per share, with an option for underwriters to buy additiona...
